repaglinide has been researched along with Coronary Artery Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeFronzo, RA; Ferrannini, E | 1 |
| Favarato, D; Garzillo, CL; Girardi, P; Hueb, W; Kalil Filho, R; Lima, EG; Rahmi, RM; Ramires, JA; Rezende, PC; Strunz, CM; Takiuti, M; Uchida, AH | 1 |
1 review(s) available for repaglinide and Coronary Artery Disease
| Article | Year |
|---|---|
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Topics: Carbamates; Clinical Trials as Topic; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Phenylalanine; Piperidines; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
1 other study(ies) available for repaglinide and Coronary Artery Disease
| Article | Year |
|---|---|
Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease.
Topics: Adamantane; Aged; Carbamates; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Ischemic Preconditioning; Male; Middle Aged; Nitriles; Piperidines; Prospective Studies; Pyrrolidines; Vildagliptin | 2013 |